Home> #BIGDATAFORBLOODCANCER campaign for patients/general audience: september 2021 - July 2022> What and why? Let us explain.
August 25, 2021 12:51 - x 00, 0 - 00:00
Video one: Explaining Big Data and blood cancers: an introduction
This video provides a short introduction to Big Data and illustrates how HARMONY is using such data to accelerate the development of new treatments for Blood Cancer.
Video two: Explaining the need for Big Data
The second video communicates why Big Data are essential for conducting novel, large-scale research that accelerates drug development, regulatory evaluation, access appraisal and treatment strategies in Blood Cancer.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
